The Canadian-based psychedelics company Nirvana Life Sciences Inc. filed a patent for the deuterated form of 7-hydroxymitragynine (D7-h.), commonly known as Kratom. Nirvana focuses on developing mental health therapeutics including non-addictive chronic pain and relapse-preventing products.

Recognition and use of Kratom, utilized in Southeast Asia for the past 150 years, has increased in Canada, the U.S. and worldwide in recent years though there is still a lack of research regarding the plant’s various active components.

Kratom is said to produce a stimulant effect when its fresh leaves are chewed and an analgesic and relaxing effect if brewed into a tea. Apparently, people who take kratom do …

Full story available on